Skip to main content

Table 1 Demographics and baseline characteristics

From: Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD

  BDP/FF FP/S
  (N = 211) (N = 207)
Gender:   
 Male (%) 155 (73.5) 143 (69.1)
 Female (%) 56 (26.5) 64 (30.9)
Age, years 63.8 (8.2) 63.7 (8.6)
BMI, kg/m 2 26.16 (5.37) 27.02 (5.60)
Smoking habits:   
 Ex-smokers (%) 106 (50.2) 121 (58.5)
 Current smokers (%) 105 (49.8) 86 (41.5)
 No. of pack years 40.1 (20.4) 41.9 (23.0)
Previous treatments* (%)   
 Long-acting anticholinergic 139 (65.9) 140 (63.6)
 LABA 51 (24.2) 44 (21.3)
 ICS/LABA fixed combination 119 (56.4) 126 (60.9)
 ICS 36 (17.1) 28 (13.5)
Pre-dose FEV1, litre 1.13 (0.40) 1.10 (0.36)
Pre-bronchodilator FEV1, litre 1.13 (0.33) 1.10 (0.30)
Post- bronchodilator FEV1, litre 1.31 (0.32) 1.29 (0.33)
Post- bronchodilator FEV1/FVC (%) 44.2 (9.7) 44.4 (9.8)
Post- bronchodilator FEV1 (% predicted normal) 46.5 (9.6) 46.4 (9.8)
FEV1 post-bronchodilator change (%) 17.5 (11.0) 17.8 (11.0)
BDI score 6.1 (1.8) 6.1 (1.7)
SGRQ score 47.0 (16.7) 45.2 (16.5)
pre-dose 6MWT, metres 352 (106) 364 (109)
Symptom score 6.27 (3.57) 6.05 (3.72)
Symptom-free days (%) 7.55 (20.14) 7.21 (20.59)
Rescue medication-free days (%) 44.27 (42.10) 39.69 (39.86)
Patients with no exacerbations in the previous year 116 (55.0%) 108 (52.2%)
  1. All values are presented as mean (SD) or absolute number (%).
  2. BDP/FF, beclomethasone dipropionate/formoterol fumarate; FP/S, fluticasone propionate/salmeterol; BMI, body mass index; LABA, long-acting β2-agonist; ICS, inhaled corticosteroids; FEV1, forced expiratory volume in the first second, FVC, Forced Vital Capacity; BDI, basal dyspnoea index; SGRQ, St. George’s respiratory questionnaire; 6MWT, 6 minutes walking test.
  3. *patients can have more than one treatment. Evaluated in the screening visit (before and after salbutamol inhalation).